NFKB1 and urinary bladder carcinoma: In this study, we assessed NF‐κB signaling in human bladder cancer samples before and after chemotherapy and assessed the efficacy and toxicity in preclinical bladder cancer models of an NF‐κB inhibitor dimethylaminoparthenolide (DMAPT) which has advanced to clinical trials.